aibioBioAge sells $115 million of stock at $19.50 after NLRP3 pill cuts CRP 86% in obese patients
Tickers BIOA
BioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor.
Key facts
- Company
- BioAge Labs, Inc. (NASDAQ: BIOA)
- News type
- Financings
- Primary source
- BioAge Labs (SEC Form 8-K)
BioAge Labs sold 5,897,435 shares of common stock at $19.50 each under an underwriting agreement dated Jan. 21, 2026. The offering raised about $115 million before fees by simple multiplication, and the company estimated net proceeds at about $107.6 million.
What happened
The Emeryville, California, company develops drugs for metabolic disease by targeting the biology of human aging. It priced the sale nine days after releasing more interim phase 1 data on BGE-102, an oral, brain-penetrant NLRP3 inhibitor.
In a multiple-ascending-dose cohort of people with obesity and hsCRP above 3 mg/L, BGE-102 at 120 mg once daily produced a median 86% drop in high-sensitivity C-reactive protein at Day 14. In that cohort, 13 of 14 participants, or 93%, reached hsCRP below 2 mg/L. Median IL-6 fell 44% and fibrinogen fell 30%. The company reported adverse events as infrequent, mild to moderate and self-limited, with no dose-limiting toxicities.
Deal terms
The 8-K gives underwriters a 30-day option for up to 884,615 more shares. Goldman Sachs, Piper Sandler and Citigroup acted as representatives. Closing was expected Jan. 23. The shares came off a Form S-3 shelf that became effective on Nov. 25, 2025. The filing did not name the buyers.
BioAge said it would combine the proceeds with existing cash to fund research, clinical and process development and manufacturing for BGE-102 and its NLRP3 and APJ programs. It listed working capital, capital expenditures, debt reduction and general corporate purposes as other uses. The filing excerpt reviewed does not state a cash balance or runway.
Why it matters
NLRP3 is a protein complex that drives inflammation through IL-1 and IL-6. High CRP is linked to cardiovascular risk, which is why companies are testing whether blocking this pathway lowers it. BioAge said in the Jan. 12 release that it expects full phase 1 data, including two more cohorts in obese participants, in the first half of 2026. It also plans to start a phase 2a study in the first half, enrolling about 100 patients randomized 1:1 to BGE-102 or placebo for 12 weeks, with percent change in hsCRP as the primary endpoint and a readout in the second half of 2026.
Five days earlier, Monte Rosa had reported that its oral NEK7 degrader cut CRP by 85% after four weeks in a small cohort, as covered in a separate Monte Rosa report. Monte Rosa also raised money after its data, in a $300 million offering priced Jan. 8.
What it means for investors
The financing gives BioAge room to run its phase 2a study. The data so far are from a handful of treated participants, 14 in the reported cohort, and from healthy volunteers and obese people at a biomarker level. CRP reductions say a drug hits its target. They do not show fewer cardiovascular events, and the study will need to show benefit in a larger group with a placebo comparator.
Cross-trial comparisons with Monte Rosa or with older NLRP3 programs should be treated cautiously. Baseline CRP, population, dose and length of treatment all differ. BioAge's cohort had a median baseline hsCRP of 4.85 mg/L; Monte Rosa reported 6.3 mg/L in its cohort. Those are different starting points.
BioAge describes BGE-102 as brain penetrant and reported cerebrospinal fluid drug levels above the IC90 at doses of 60 mg and above in earlier data, but the present results concern cardiovascular risk markers. The raise adds 5.9 million shares on the base deal, and the next test is whether phase 2a data hold up.
What to watch
Full phase 1 results and the start of the phase 2a trial are both guided to the first half of 2026. The phase 2a readout is guided to the second half of 2026.